Abstract
In the past, our limited understanding of the processes involved in the initiation and growth of cancer hindered our ability to effectively treat most human malignancies and therapies were often associated with significant toxic side effects as well as re-emergence of disease. The development of drug delivery systems such as liposomes has improved the specificity of various conventional anticancer agents by enhancing drug accumulation in tumors while often decreasing exposure to susceptible healthy tissues. More recently, the identification of a wide range of genes and corresponding protein products that are altered in various human cancers has revealed new molecular targets for cancer therapy that may provide improved selectivity for tumor cells over traditional cytotoxic agents. This review discusses how advances in the sophistication of liposomal delivery systems may open new opportunities for combining novel molecular targeting strategies with pharmacological targeting via liposomes to optimize the therapy of many human malignancies.
Similar content being viewed by others
References
Lasic DD, Papahadjopoulos D: Science 267: 1275-1276, 1995
Mastrangelo MJ, Berd D, Mathan FE, Lattime EC: Sem Oncol 23: 4-21, 1996
Mayer LD, Tai LCL, Ko DSC, Masin D, Ginsberg RS, Cullis PR, Bally MB: Cancer Res 49: 5922-5930, 1989
Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z: Cancer Res 42: 4734-4739, 1982
Huang SK, Mayhew E, Gilani S, Lasic DD, Martin FJ, Papahadjopoulos D: Cancer Res 52: 6774-6781, 1992
Mayer LD, Dougherty G, Harasym TO, Bally MB: J Pharmacol Exp Therapeut 280: 1406-1414, 1997
Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK: Cancer Res 54: 3352-3356, 1994
Webb MS, Harasym TO, Masin D, Bally MB, Mayer LD: Br J Cancer 72: 896-904, 1995
Subramanian D, Muller MT: Oncol Res 7: 461-469, 1995
Huang SK, Stauffer PR, Hong K, Guo JW, Phillips TL, Huang A, Papahadjopoulos D: Cancer Res 54: 2186-2191, 1994
Holland JW, Hui C, Cullis PR, Madden TD: Biochemistry 35: 2618-2624, 1996
Kirpotin D, Hong K, Mullah N, Papahadjopoulos D, Zalipsky S: FEBS Lett 388: 115-118, 1996
Ahmad I, Longenecker M, Samuel J, Allen TM: Cancer Res 53: 1484-1488, 1993
Marjan J, Charrios G, Lopes de Menezes D, Allen TM: Proc Amer Assoc Cancer Res 37: A2103, 1996
Lee RJ, Low PS: J Biol Chem 269: 3198-3204, 1994
Park JW, Hong K, Kirpotin DB, Papahadjopoulos D, Benz CC: Adv Pharmacol 40: 400-435, 1997
Mizuguchi H, Nakanishi M, Nakanishi T, Nakagawa T, Nakagawa S, Mayumi T: Br J Cancer 73: 472-476, 1996
Suzuki S, Inoue K, Hongoh A, Hashimoto Y, Yamazoe Y: Br J Cancer 76: 83-89, 1997
Gibbs JB, Oliff A: Ann Rev Pharmacol Toxicol 37: 143-166, 1997
Prins I, de Vries EGF, Mulder NH: Clin Oncol 5: 245-252, 1994
Hynes NE, Stern DF: Biochim Biophys Acta 1198: 165-184, 1994
Kartner N, Riorden JR, Ling V: Science 221: 1285-1288, 1983
Hickman JA: Eur J Cancer 32A: 921-926, 1996
Fan D, Beltran PJ, O'Brian CA: In: Kellen JA (ed) Reversal of Multidrug Resistance in Cancer. CRC Press, Boca Raton pp. 93-125, 1994
Gonzalez O, Colombo T, De Fusco M, Imperatori L, Zuechetti M, D'Incalci M: Cancer Chemother Pharmacol 36: 335-340, 1995
Weeb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Lancet 349: 1137-1141, 1997
Cotter F, Hohnson P, Hall P, Pocock C, Al Mahdi N, Cowell J, Morgan G: Oncogene 9: 3049-3055, 1994
Felgner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielson M. Proc Natl Acad Sci USA 84: 7413-7417, 1987
Hofland H, Huang L: Biochem Biophys Res Commun 207: 492-496, 1995
Li S, Huang L: Gene Therapy 4: 891-900, 1997
Hong K, Zheng W, Baker A, Papahadjopoulos D: FEBS Lett 400: 233-237, 1997
Krishna R, Mayer LD: Cancer Res 57: 5246-5253, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mayer, L.D. Future developments in the selectivity of anticancer agents: Drug delivery and molecular target strategies. Cancer Metastasis Rev 17, 211–218 (1998). https://doi.org/10.1023/A:1006070906949
Issue Date:
DOI: https://doi.org/10.1023/A:1006070906949